{"id":10642,"date":"2026-02-03T12:18:18","date_gmt":"2026-02-03T06:48:18","guid":{"rendered":"https:\/\/indianpharmanetwork.co.in\/medicines\/?post_type=product&#038;p=10642"},"modified":"2026-02-03T12:21:08","modified_gmt":"2026-02-03T06:51:08","slug":"cablivi-caplacizumab-yhdp-injection","status":"publish","type":"product","link":"https:\/\/indianpharmanetwork.co.in\/medicines\/product\/cablivi-caplacizumab-yhdp-injection\/","title":{"rendered":"Cablivi (Caplacizumab-yhdp) Injection"},"content":{"rendered":"<p><strong>Caplacizumab, sold under the brand name Cablivi, is a monoclonal antibody used for the treatment of thrombotic thrombocytopenic purpura.<\/strong> Caplacizumab is indicated for the treatment of acquired thrombotic thrombocytopenic purpura, in combination with plasma exchange and immunosuppressive therapy.<\/p>\n<p>Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disorder that is even more uncommon in children, only occurring in about 1 per 10 million children annually. aTTP causes blood clots in the small blood vessels. These clots can slow or block the flow of blood to parts of the heart, brain, kidneys, and other organs. In this disorder, platelets (blood cells involved in clotting) clump together, leaving fewer platelets in the rest of the body to help with clotting. In addition, red blood cells may break apart, causing anemia.<\/p>\n<h4>CABLIVI (caplacizumab-yhdp) for injection, for intravenous or subcutaneous use<br \/>\nInitial U.S. Approval: 2019<\/h4>\n<h4>Contact IPN \u2013 Cablivi Access in India<\/h4>\n<p><strong>For inquiries regarding availability, import process, or cost of Cablivi (Caplacizumab-yhdp) Injection :<\/strong><br \/>\n<strong>India Pharma Network (IPN)<\/strong>\u00a0: Headquartered in\u00a0<strong>New Delhi<\/strong>, with branch offices in\u00a0<strong>Delhi, Gurugram, Mumbai, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur\u00a0<\/strong>and<strong>\u00a0Lucknow<\/strong>, IPN supports medicine imports across India on a\u00a0<strong>Named Patient Import Basis<\/strong>\u00a0and for\u00a0<strong>personal use only<\/strong>.\u00a0<strong>Mobile\/WhatsApp:<\/strong>\u00a0Mr. Tarun: +91 9891 296 838 | \u00a0Mr. Neeraj: +91 9811 747 774.<strong>\u00a0Email:<\/strong>\u00a0<a href=\"mailto:info@indianpharmanetwork.co.in\" target=\"_blank\" rel=\"noopener\">info@indianpharmanetwork.co.in<\/a><\/p>\n<p>NEWS\/UPDATES<\/p>\n<ul>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-therapy-rare-blood-disorder-pediatric-patients-12-years-and-older\" target=\"_blank\" rel=\"noopener\">FDA approves therapy for rare blood disorder in pediatric patients 12 years and older.<\/a><\/li>\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approved-caplacizumab-yhdp\" target=\"_blank\" rel=\"noopener\">FDA approved caplacizumab-yhdp.<\/a><\/li>\n<li><a href=\"https:\/\/www.contemporarypediatrics.com\/view\/fda-approves-caplacizumab-for-pediatric-acquired-thrombotic-thrombocytopenic-purpura\" target=\"_blank\" rel=\"noopener\">FDA approves caplacizumab for pediatric acquired thrombotic thrombocytopenic purpura.<\/a><\/li>\n<li><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/fda-approves-sanofi-cablivi\/\" target=\"_blank\" rel=\"noopener\">FDA approves Sanofi\u2019s Cablivi as first therapy for rare blood disorder.<\/a><\/li>\n<\/ul>\n<h5>Compliance &amp; Disclaimer<\/h5>\n<p>India Pharma Network acts solely as a facilitator for Cablivi (Caplacizumab-yhdp) Injection access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:<\/p>\n<ul>\n<li>Strictly on a Named Patient Import Basis<\/li>\n<li>Exclusively for personal use<\/li>\n<li>Not for resale, distribution, or commercial sale<\/li>\n<li>Subject to applicable Indian laws and regulatory approvals<\/li>\n<\/ul>\n<p>The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.<\/p>\n","protected":false},"excerpt":{"rendered":"<h2>Cablivi (Caplacizumab-yhdp) \u2013 thrombotic thrombocytopenic purpura (aTTP) drug therapy in India.<\/h2>\n<p>CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.<\/p>\n<table border=\"1\" width=\"95%\">\n<tbody>\n<tr>\n<td><strong>Brand Name:<\/strong><\/td>\n<td>Cablivi<\/td>\n<\/tr>\n<tr>\n<td><strong>Generic Name:<\/strong><\/td>\n<td>Caplacizumab-yhdp Injection<\/td>\n<\/tr>\n<tr>\n<td><strong>Strength:<\/strong><\/td>\n<td>\u2022 For injection: 11 mg as a lyophilized powder in a single-dose vial.<\/td>\n<\/tr>\n<tr>\n<td><strong>Manufacturer:<\/strong><\/td>\n<td>Ablynx US<\/td>\n<\/tr>\n<tr>\n<td><strong>Approved By:<\/strong><\/td>\n<td>EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Source Details:\u00a0<a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761112s007lbl.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Patient Information<\/strong>.<\/a><br \/>\n<strong><em>Cablivi must always be used under the supervision of a Registered Medical Practitioner (RMP).<\/em><\/strong><\/p>\n<h3>Access Cablivi for aTTP on a Named Patient Import Basis<\/h3>\n<p><strong>IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to Cablivi (Caplacizumab-yhdp) for personal use. <\/strong>To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).<\/p>\n<p><strong>For any queries, including information regarding the cost of the pharmaceutical product in India<\/strong>, please contact the IPN Healthcare Support Team via email or at the following numbers:\u00a0<strong>Mobile\/WhatsApp:<\/strong>\u00a0Mr. Tarun: +91 9891 296 838 | \u00a0Mr. Neeraj: +91 9811 747 774.<\/p>\n<p><em><strong>Note:<\/strong>\u00a0All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.<\/em><\/p>\n","protected":false},"featured_media":10643,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":""},"product_brand":[],"product_cat":[180],"product_tag":[],"class_list":{"0":"post-10642","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-blood-disorders","8":"first","9":"instock","10":"shipping-taxable","11":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/product\/10642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/media\/10643"}],"wp:attachment":[{"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/media?parent=10642"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/product_brand?post=10642"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/product_cat?post=10642"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/indianpharmanetwork.co.in\/medicines\/wp-json\/wp\/v2\/product_tag?post=10642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}